BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

By Maggie Fick and Kashish Tandon LONDON/BENGALURU (Reuters) -Drugmaker stocks gained a temporary reprieve on Thursday as U.S ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...

(Alliance News) - BioPharma Credit PLC on Wednesday said it has received a USD8.3 million settlement payment from Biogen Inc as the final resolution of a loan dispute.

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., ...

Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Shares of Biogen Inc. shed 3.52% to $132.03 Tuesday, on what proved to be an all-around mixed trading session for the stock ...